September 21, 2017
CGPA Statement on the Provisional Application of CETA and New Pharmaceutical Intellectual Property Measures for Canada
Toronto, September 21, 2017 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding today’s provisional application of the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union, which includes extensive changes to Canada’s intellectual property regime for pharmaceuticals.
July 16, 2017
Agreement in Principle Between the Government of Quebec and Canadian Generic Pharmaceutical Association (CGPA)
Montreal, July 16, 2017 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the Agreement in Principle announced today between the Government of Quebec and CGPA.
February 27, 2017
Larry MacGirr of Pharmascience Elected Chair of Canadian Generic Pharmaceutical Association Doug Sommerville of Teva Canada Elected Vice Chair
Toronto, February 27, 2017 – The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the election of Mr. Larry MacGirr, Chief Operating Officer of Pharmascience, as Chair of CGPA, and Mr. Doug Sommerville, Senior Vice President and General Manager of Teva Canada, as Vice Chair of CGPA.
February 17, 2017
Toronto, February 17, 2017 - The Joint 23rd Medicines for Europe and 20th IGBA Annual Conference will unite over 300 experts from the generic and biosimilar sector to provide market trends, innovative commercial strategies, new updates and opportunities for growth for affordable medicines.